LGND Ligand Pharmaceuticals Incorporated

+1.89  (+2%)
Previous Close 112.58
Open 113.23
Price To Book 2.08
Market Cap 2243429420
Shares 19,598,405
Volume 244,102
Short Ratio
Av. Daily Volume 395,685

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
Data due by the end of 3Q 2019.
Refractory status epilepticus (RSE)
Data due first half of 3Q 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 3 top-line data due 2H 2020.
Sparsentan - DUPLEX
Focal segmental glomerulosclerosis (FSGS)
Phase 2b trial to be initiated 2H 2019.
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 3 top-line data due mid-2020.
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Data due first half of 3Q 2019.
Ganaxolone - oral (Amaryllis)
Postpartum depression
sNDA filed April 2019.
Community-acquired bacterial pneumonia (CABP)
Phase 3 data due 1H 2022.
IgA nephropathy
Phase 2 data due 3Q 2019.
RPL554 DPI formulation
Maintenance treatment of COPD
Phase 1 top-line data due 3Q 2019.
Captisol-enabled (CE) Iohexol program
Contrast-induced Nephropathy

Latest News

  1. Ligand Grants Preclinical Candidate Rights to UK-based Firm
  2. Ligand Licenses VER250840 to Cumulus Oncology
  3. Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $283,750 of Shares
  4. A Closer Look At Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Impressive ROE
  5. AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates
  6. Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View
  7. Edited Transcript of LGND earnings conference call or presentation 2-May-19 8:30pm GMT
  8. Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss
  9. Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1
  10. See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.
  11. Novan adds more cash, now confident it can execute
  12. Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.
  13. Novan Completes Funding Transaction with Ligand Pharmaceuticals
  14. Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
  15. The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen
  16. Ligand Pharmaceuticals Incorporated (LGND) Q1 2019 Earnings Call Transcript
  17. Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates
  18. Ligand: 1Q Earnings Snapshot
  19. Ligand Reports First Quarter 2019 Financial Results
  20. Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol